MYGN vs PRTC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MYGN exhibits severe operational distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a fundamental collapse in financial health. While the balance sheet remains liquid with a strong current ratio (2.67) and low debt-to-equity (0.33), these are lagging indicators compared to the alarming -20.80% YoY revenue decline and -41.29% profit margin. The stock is in a long-term secular decline, losing over 82% of its value over five years, and current valuation is supported only by asset value (P/B 1.25) rather than earnings power.
PRTC presents a contradictory financial profile with a stable Piotroski F-Score of 5/9 and a strong liquidity position (Current Ratio 8.49), yet suffers from severe operational inefficiency. While the Graham Number of $24.47 suggests defensive value, the growth-based intrinsic value of $11.90 and a negative forward P/E indicate significant future earnings risk. The massive discrepancy between the reported profit margin (792.96%) and operating margin (-2589.52%) suggests the company is relying on non-operating gains rather than core business profitability. Short-term price momentum is positive, but long-term performance remains deeply depressed.
Compare Another Pair
Related Comparisons
MYGN vs PRTC: Head-to-Head Comparison
This page compares Myriad Genetics, Inc. (MYGN) and PureTech Health plc (PRTC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.